{"groups":[{"description":"Idelalisib (Zydelig®) 150 mg tablet orally twice daily + rituximab 375 mg/m\\^2 intravenously starting on Day 1 for a total of 8 infusions","id":"FG000","title":"Idelalisib + Rituximab"},{"description":"Placebo tablet orally twice daily + rituximab 375 mg/m\\^2 intravenously starting on Day 1 for a total of 8 infusions","id":"FG001","title":"Placebo + Rituximab"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"105"},{"groupId":"FG001","numSubjects":"55"}],"type":"Study Terminated by Sponsor"},{"reasons":[{"groupId":"FG000","numSubjects":"27"},{"groupId":"FG001","numSubjects":"4"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"14"},{"groupId":"FG001","numSubjects":"7"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"1"}],"type":"Other"},{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"2"}],"type":"Initiation of Other Anti-Cancer Therapy"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"198"},{"groupId":"FG001","numSubjects":"97"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"42"},{"groupId":"FG001","numSubjects":"28"}],"comment":"Completed = reached primary efficacy endpoint of progressive disease or death","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"156"},{"groupId":"FG001","numSubjects":"69"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"385 participants were screened.","recruitmentDetails":"Participants were enrolled at study sites in the North America, Europe, and Asia Pacific. The first participant was screened on 16 January 2013. The last study visit occurred on 18 May 2016."}